Cargando…
New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review
BACKGROUND: New-onset sarcoidosis has been previously described in three case reports in patients affected by rheumatoid arthritis treated with tocilizumab (TCZ). The existence of a cause–effect mechanism between the biological treatment and the onset of the illness is still being debated. PATIENT C...
Autores principales: | Del Giorno, Rosaria, Iodice, Alfonso, Mangas, Cristina, Gabutti, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463335/ https://www.ncbi.nlm.nih.gov/pubmed/31019572 http://dx.doi.org/10.1177/1759720X19841796 |
Ejemplares similares
-
Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013) -
Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022) -
Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022) -
Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018) -
Vision loss in patients with giant cell arteritis treated with tocilizumab
por: Amsler, Jennifer, et al.
Publicado: (2021)